{
    "2019-03-27": [
        [
            {
                "time": "2019-03-26",
                "original_text": "Novartis (NVS) Receives FDA Approval for MS Drug Mayzent",
                "features": {
                    "keywords": [
                        "FDA",
                        "Approval",
                        "MS Drug",
                        "Mayzent"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-25",
                "original_text": "Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study",
                "features": {
                    "keywords": [
                        "Xyrem",
                        "Phase III",
                        "Study",
                        "Success"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-27",
                "original_text": "The Hits Just Keep Coming For Biogen As Rival Gains MS Drug Approval",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Rival",
                        "MS Drug",
                        "Approval"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-03-26",
                "original_text": "Novartis MS drug wins FDA's blessing amid scrutiny of $88k annual price",
                "features": {
                    "keywords": [
                        "FDA",
                        "Approval",
                        "Price Scrutiny",
                        "$88k"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-28",
                "original_text": "6 Gene Therapy M&A Targets On The Radar",
                "features": {
                    "keywords": [
                        "Gene Therapy",
                        "M&A",
                        "Targets"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-26",
                "original_text": "Novartis Multiple Sclerosis Drug With Price Tag of $88,000 Gets FDA Nod",
                "features": {
                    "keywords": [
                        "FDA",
                        "Approval",
                        "Price Tag",
                        "$88,000"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-26",
                "original_text": "FDA Approves Novartis Drug To Treat More Severe Form Of Multiple Sclerosis",
                "features": {
                    "keywords": [
                        "FDA",
                        "Approval",
                        "Severe Form",
                        "MS"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-26",
                "original_text": "The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",
                "features": {
                    "keywords": [
                        "FDA",
                        "Nod",
                        "Novartis",
                        "Jazz",
                        "Late-Stage",
                        "Data",
                        "Genfit IPO"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-26",
                "original_text": "Novartis new MS drug Mayzent to be priced at $88,000 per year",
                "features": {
                    "keywords": [
                        "Novartis",
                        "MS Drug",
                        "Mayzent",
                        "Priced",
                        "$88,000"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-26",
                "original_text": "Novartis gets U.S. approval for new drug to treat multiple sclerosis",
                "features": {
                    "keywords": [
                        "Novartis",
                        "U.S.",
                        "Approval",
                        "New Drug",
                        "MS"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}